Halcygen (ASX:HGN) to expand board following departure of director and COO

Melbourne-based generic pharmaceutical manufacturer, Halcygen Pharmaceuticals (ASX:HGN), is seeking to add new talent to its board and senior management following the departure of Executive Director and COO, Craig Bottomley yesterday.

Bottomley, who had been with the company for five years, stepped down for family reasons.

“The board and I would like to thank Craig Bottomley for his significant contribution to the company,” said Halcygen’s CEO, Dr Roger Aston. “He has played a key role in establishing the Halcygen business and in the transformation of the company following the acquisition of Mayne Pharma International Pty Ltd in 2009.”

Halcygen has brought on Lisa Pendlebury into the role of Investor Relations Manager, taking over those responsibilities from the departing Bottomley. Pendlebury was formerly Investor Relations Manager at Pacific Brands, where she spent seven years across several roles.

The company is currently recruiting a replacement for Bottomley to take over his role as Executive Director and COO.

The company is also looking an experienced non-executive board member, said Aston. “We’re looking for someone familiar with compliance issues for the ASX and ASIC, general business acumen and the ability to participate in various sub-committees. Someone who can assist us in growing the business into global markets, particularly on the retail side rather than the pharmaceutical side.”

Halcygen is also seeking to recruit new senior management to help drive new projects here and overseas. “There are always opportunities for people as new projects come into fruition,” said Aston.

The new roles will specifically be in project management and project leadership, such as in getting products registered overseas, managing licensing and identifying new market opportunities, said Aston.

Halcygen Pharmaceuticals Limited (ASX:HGN) share price is level today at 57.5c.